GlassScriptPhysician profile
Prathik Krishnan
NPI 1134533169
$5,272.88
in general payments reported to CMS, 2019-2025
30 companies · $1,165 in 2025
The $1,165 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $120 · 2021: $469 · 2022: $432 · 2023: $2,170 · 2024: $917 · 2025: $1,165.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,954 · Travel and Lodging: $1,238 · Education: $58.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,954.38 |
| Travel and Lodging | $1,238.43 |
| Education | $58.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pulmonx Corporation | $1,502.84 | 2023 | Pulmonx Chartis Tablet Console, Chartis Catheter, Zephyr Endobronchial Valve |
| Astrazeneca Pharmaceuticals LP | $620.70 | 2022-2025 | Fasenra, Tezspire, Airsupra |
| Glaxosmithkline, LLC. | $604.17 | 2020-2025 | Nucala |
| Merck Sharp & Dohme LLC | $378.44 | 2020-2025 | Zerbaxa, Winrevair, Recarbrio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $376.19 | 2021-2025 | Ofev |
| Insmed, INC. | $332.76 | 2021-2025 | Arikayce, Brinsupri |
| Actelion Pharmaceuticals US, INC. | $301.12 | 2020-2025 | Opsumit |
| Inari Medical, INC. | $131.17 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Olympus America INC. | $122.80 | 2024 | Spiration Valve System |
| Takeda Pharmaceuticals U.S.A., INC. | $111.56 | 2023-2025 | Glassia |
| Regeneron Healthcare Solutions, INC. | $103.67 | 2024-2025 | Dupixent |
| Janssen Pharmaceuticals, INC | $83.32 | 2020-2024 | Xarelto |
| Alexion Pharmaceuticals, INC. | $67.63 | 2021-2025 | Ultomiris |
| Inogen, INC. | $59.24 | 2023-2025 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Genzyme Corporation | $53.47 | 2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verona Pharma, INC. | $53.07 | 2025 | Ohtuvayre |
| E.R. Squibb & Sons, L.L.C. | $50.26 | 2020-2021 | |
| Mallinckrodt Hospital Products INC. | $39.90 | 2025 | Acthar, Terlivaz |
| Pfizer INC. | $37.66 | 2020-2021 | |
| Inspire Medical Systems, INC. | $36.99 | 2025 | Inspire |
| Intuitive Surgical, INC. | $36.13 | 2024 | |
| Genentech USA, INC. | $35.50 | 2022 | |
| Pinnacle Biologics, INC | $27.53 | 2024 | Photofrin |
| Itamar Medical INC | $22.43 | 2024 | Watchpatone |
| Grifols USA, LLC | $20.36 | 2021 | |
| Gilead Sciences, INC. | $17.18 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.14 | 2023 | |
| La Jolla Pharmaceutical Company | $15.28 | 2024 | Giapreza |
| Philips North America LLC | $14.37 | 2025 | Vest Therapy Und |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prathik Krishnan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.